Colon Adenocarcinoma, Rectal Adenocarcinoma, Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Conditions
Brief summary
This phase I/II trial studies the side effects and best dose of nintedanib when given together with capecitabine and to see how well they work in treating patients with colorectal cancer that has not responded to previous treatment (refractory) and has spread to other places in the body (metastatic). Nintedanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also block the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nintedanib with capecitabine may be a better treatment for colorectal cancer.
Detailed description
PRIMARY OBJECTIVES: * I. To estimate the maximum tolerated dose (MTD) and examine the dose-limiting toxicities of nintedanib when administered with capecitabine within the study population and, establish the recommended phase II dose (RP2D). (Phase I) * II. To assess progression free survival at 18 weeks. (Phase II) SECONDARY OBJECTIVES: * I. To assess median progression free survival. (Phase II) * II. To assess median overall survival from the date of enrollment to the time of death will be documented. (Phase II) * III. To assess the objective response rate as measured by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. (Phase II) * IV. To assess the toxicity of dose regimen using the Cancer Therapy Evaluation Program (CTEP) National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE version 4.0). (Phase II) TERTIARY OBJECTIVES: * I. Measurement of circulating angiogenic cytokines (CAFs): vascular endothelial growth factor (VEGF), soluble vascular endothelial growth factor receptor (sVEGFR) 1/2, placental growth factor (PlGF), granulocyte macrophage colony-stimulating factor (GMCSF), leptin, interleukin (IL)-1 alpha (a), IL-8, IL-6, fibroblast growth factor basic (FGFb), osteopontin and pentraxin-3. (Phase II) * II. Measurement of drug levels and pharmacokinetic (PK)/pharmacodynamic (PD) modeling. (Phase II) OUTLINE: This is a phase I, dose-escalation study of nintedanib followed by a phase II study. Patients receive capecitabine orally (PO) twice daily (BID) (every 12 hours) on days 1-14 and nintedanib PO BID (every 12 hours) on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days, every 28 days until resolution or satisfactory stabilization of persistent drug-related toxicity, and then every 6 months thereafter.
Interventions
DRUGCapecitabine
Given PO
OTHERLaboratory Biomarker Analysis
Correlative studies
DRUGNintedanib
Given PO
OTHERPharmacological Study
Correlative studies
Sponsors
National Cancer Institute (NCI)
Boehringer Ingelheim
National Comprehensive Cancer Network
Roswell Park Cancer Institute
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Hemoglobin \>= 9 g/dL * Absolute neutrophil count \>= 1500/mm\^3 * Platelet count \>= 100,000/mm\^3 * Creatinine =\< 1.5 upper limit of normal (ULN) AND creatinine clearance (CrCl) \> 50 mL/min by Cockcroft-Gault equation * Males = (140 -age (yrs) (body weight (kg)/(72) (serum creatinine) (mg/dL) * Females = 0.85 \* (140-age (yrs) (body weight (kg)/(72)(serum creatinine (mg/dL) * Bilirubin \< ULN * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 1.5 ULN if without liver metastases * AST/ALT =\< 2.5 x ULN if with liver metastases * Coagulation parameters: international normalized ratio (INR) =\< 2, prothrombin time (PT) and partial thromboplastin time (PTT) \< 1.5 X institutional ULN * Have measurable disease per RECIST 1.1 criteria * Histologically or cytologically proven adenocarcinoma of the colon or rectum * Prior progression following a fluoropyrimidine-based therapy and progression following or intolerance to irinotecan and oxaliplatin, as well as anti-epidermal growth factor receptor (EGFR) therapy (e.g., panitumumab or cetuximab) for rat sarcoma viral oncogene homolog (RAS) wild-type patients * Ability to swallow and retain oral medication * Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for three months following completion of therapy; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately * Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
Exclusion criteria
* Prior treatment with nintedanib * Prior treatment with regorafenib * Major injuries or surgery within the 4 weeks prior to initiation of therapy with incomplete wound healing or planned surgery during the on-study treatment period * Uncontrolled hypertension: systolic blood pressure \>= 160, diastolic blood pressure \>= 90 * Urine protein/creatinine ratio \>= 1.0 * History of clinically significant hemorrhagic or thrombotic event within the past 6 months, not including uncomplicated catheter-associated venous thrombosis; patients on anti-coagulation are not permitted to be on any oral formulations (warfarin, rivaroxaban, dabigatran, etc.) due to concern for drug-drug interaction * Unstable angina, symptomatic congestive heart failure or cardiac arrhythmia requiring anti-arrhythmic therapy (beta-blockers, calcium channel blockers and digoxin are allowed) * History of cerebrovascular or myocardial ischemia within 6 months of initiation * Known inherited predisposition to bleeding or thrombosis * Known active or chronic hepatitis B or C or human immunodeficiency virus (HIV) * Untreated brain metastases * History of second primary malignancy diagnosed within 3 years prior to enrollment, excluding: * In-situ cervical carcinoma * Superficial bladder cancer * Non-melanoma skin cancer * Stage I breast cancer * Low grade (Gleason =\< 6) localized prostate cancer * Any additional malignancy which has been in clinical remission for at least 1 year * Pregnant or nursing female participants * Unwilling or unable to follow protocol requirements * Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study drug * Received an investigational agent within 4 weeks prior to enrollment * PHASE I: History of intolerance to capecitabine at doses =\< 1000 mg/m\^2 BID, as defined by documented \>= grade 3 hand-foot syndrome, documented severe diarrhea requiring hospitalization, or other documented severe adverse events (AEs) attributable to capecitabine * PHASE II: History of intolerance to capecitabine at doses below 1000 mg/m\^2 BID, as defined by documented \>= grade 3 hand-foot syndrome; documented severe diarrhea requiring hospitalization; or other documented severe AEs attributable to capecitabine
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To Examine the DLT | At least 21 days. | The recommended Phase II dose is of the Nintedanib and Capecitabine combination is defined as the dose level that causes dose limiting toxicities (DLTs) in ≤ 1 out of 6 patients at highest dose level below the maximally administered dose. Capecitabine is fixed dose at 2000 mg/m2; while Nintedanib is evaluated at 150mg (dose level 1) and 200 mg (dose level 2). |
| Progression Free Survival (PFS) Rate, Defined as the Proportion of Patients Who Survive Without Disease Progression Via the RECIST Version 1.1 (Phase II) | At 18 weeks | Progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions (the sum must also demonstrate an absolute increase of at least 5 mm) or the appearance of new lesions. Will be summarized using standard Kaplan-Meier methods. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Median PFS (Phase II) | Up to 2 years | Progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions (the sum must also demonstrate an absolute increase of at least 5 mm) or the appearance of new lesions. Estimates of median PFS will be obtained with corresponding 90% confidence intervals. |
| Median OS (Phase II) | From the date of enrollment to the time of death, assessed up to 2 years | Overall survival is defined as time from date of subject enrollment to the date of death due to any cause. Estimates of median OS will be obtained with corresponding 90% confidence intervals. |
| Objective Response Rate | After every 3 cycles (9 weeks) of therapy. | Overall Response is defined as Complete Response: Disappearance of all target lesions and any lymph nodes must have a reduction in short axis to \< 10 mm; or Partial Response: At least a 30% decrease in the sum of diameters of target lesions; or Stable Disease: Neither sufficient shrinkage to qualify for partial response, nor sufficient increase to qualify for progressive disease. |
| Aggregate Rates of Adverse Events Measured by CTCAE Version 4.0 (Phase II) | Up to 30 days after the last dose of study drug | Number of Participants with Adverse Events, Graded According to the CTEP NCI Common Terminology Criteria for Adverse Events (CTCAE Version 4.0). |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Dose Level 1: Capecitabine at 2000 mg/m2, Nintedanib at 150 mg Dose Level (Arm) 1: Capecitabine at 2000 mg/m2 PO daily and Nintedanib at 150 mg PO bid
Capecitabine at 2000 mg/m2 will be administration will be twice daily for two weeks (the first 2 weeks of each 21 day cycle), followed by a 1 week rest. Nintedanib 150 mg will be administered twice daily for 21 days (i.e., 1 complete 3-week cycle). Both capecitabine and nintedanib may be taken together, with water, within 30 minutes following a meal. Doses should be separated by approximately 12 hours, with the PM dose being 12 hours (+/- 2 hours) after the AM dose. | 3 |
| Dose Level 2: Capecitabine at 2000 mg/m2,Nintedanib at 200 mg Dose Level (Arm) 2: Capecitabine at 2000 mg/m2 PO daily and Nintedanib at 200 mg PO bid
Capecitabine at 2000 mg/m2 will be administration will be twice daily for two weeks (the first 2 weeks of each 21 day cycle), followed by a 1 week rest. Nintedanib 2000 mg will be administered twice daily for 21 days (i.e., 1 complete 3-week cycle). Both capecitabine and nintedanib may be taken together, with water, within 30 minutes following a meal. Doses should be separated by approximately 12 hours, with the PM dose being 12 hours (+/- 2 hours) after the AM dose. | 39 |
| Total | 42 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 0 | 2 |
| Overall Study | Physician Decision | 0 | 2 |
| Overall Study | Withdrawal by Subject | 0 | 3 |
Baseline characteristics
| Characteristic | Total | Dose Level 1: Capecitabine at 2000 mg/m2, Nintedanib at 150 mg | Dose Level 2: Capecitabine at 2000 mg/m2,Nintedanib at 200 mg |
|---|---|---|---|
| Age, Continuous | 57.6 years | 61.0 years | 57.3 years |
| Body Weight | 77.2 Kilograms (kg) | 69.2 Kilograms (kg) | 77.8 Kilograms (kg) |
| ECOG Status at Baseline Grade 0 | 23 Participants | 2 Participants | 21 Participants |
| ECOG Status at Baseline Grade 1 | 19 Participants | 1 Participants | 18 Participants |
| Presence of liver metastasis | 23 Participants | 3 Participants | 20 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 5 Participants | 0 Participants | 5 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 3 Participants | 0 Participants | 3 Participants |
| Race (NIH/OMB) White | 33 Participants | 3 Participants | 30 Participants |
| Sex: Female, Male Female | 24 Participants | 2 Participants | 22 Participants |
| Sex: Female, Male Male | 18 Participants | 1 Participants | 17 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 3 / 3 | 32 / 39 |
| other Total, other adverse events | 3 / 3 | 39 / 39 |
| serious Total, serious adverse events | 0 / 3 | 10 / 39 |
Outcome results
Primary
Progression Free Survival (PFS) Rate, Defined as the Proportion of Patients Who Survive Without Disease Progression Via the RECIST Version 1.1 (Phase II)
Progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions (the sum must also demonstrate an absolute increase of at least 5 mm) or the appearance of new lesions. Will be summarized using standard Kaplan-Meier methods.
Time frame: At 18 weeks
Population: All treated and eligible patients at dose level 2
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Capecitabine, Nintedanib) | Progression Free Survival (PFS) Rate, Defined as the Proportion of Patients Who Survive Without Disease Progression Via the RECIST Version 1.1 (Phase II) | 41.7 percentage of participants |
Primary
To Examine the DLT
The recommended Phase II dose is of the Nintedanib and Capecitabine combination is defined as the dose level that causes dose limiting toxicities (DLTs) in ≤ 1 out of 6 patients at highest dose level below the maximally administered dose. Capecitabine is fixed dose at 2000 mg/m2; while Nintedanib is evaluated at 150mg (dose level 1) and 200 mg (dose level 2).
Time frame: At least 21 days.
Population: Patients who were evaluable for DLTs
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Capecitabine, Nintedanib) | To Examine the DLT | 200 mg |
Secondary
Aggregate Rates of Adverse Events Measured by CTCAE Version 4.0 (Phase II)
Number of Participants with Adverse Events, Graded According to the CTEP NCI Common Terminology Criteria for Adverse Events (CTCAE Version 4.0).
Time frame: Up to 30 days after the last dose of study drug
Population: All treated and eligible patients at dose level 2
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment (Capecitabine, Nintedanib) | Aggregate Rates of Adverse Events Measured by CTCAE Version 4.0 (Phase II) | Grade 1 | 3 Participants |
| Treatment (Capecitabine, Nintedanib) | Aggregate Rates of Adverse Events Measured by CTCAE Version 4.0 (Phase II) | Grade 2 | 13 Participants |
| Treatment (Capecitabine, Nintedanib) | Aggregate Rates of Adverse Events Measured by CTCAE Version 4.0 (Phase II) | Grade 3 | 16 Participants |
| Treatment (Capecitabine, Nintedanib) | Aggregate Rates of Adverse Events Measured by CTCAE Version 4.0 (Phase II) | Grade 4 | 1 Participants |
| Treatment (Capecitabine, Nintedanib) | Aggregate Rates of Adverse Events Measured by CTCAE Version 4.0 (Phase II) | Grade 5 | 3 Participants |
Secondary
Median OS (Phase II)
Overall survival is defined as time from date of subject enrollment to the date of death due to any cause. Estimates of median OS will be obtained with corresponding 90% confidence intervals.
Time frame: From the date of enrollment to the time of death, assessed up to 2 years
Population: All treated and eligible patients at dose level 2
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Capecitabine, Nintedanib) | Median OS (Phase II) | 8.9 months |
Secondary
Median PFS (Phase II)
Progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions (the sum must also demonstrate an absolute increase of at least 5 mm) or the appearance of new lesions. Estimates of median PFS will be obtained with corresponding 90% confidence intervals.
Time frame: Up to 2 years
Population: All treated and eligible patients at dose level 2
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Capecitabine, Nintedanib) | Median PFS (Phase II) | 3.4 months |
Secondary
Objective Response Rate
Overall Response is defined as Complete Response: Disappearance of all target lesions and any lymph nodes must have a reduction in short axis to \< 10 mm; or Partial Response: At least a 30% decrease in the sum of diameters of target lesions; or Stable Disease: Neither sufficient shrinkage to qualify for partial response, nor sufficient increase to qualify for progressive disease.
Time frame: After every 3 cycles (9 weeks) of therapy.
Population: All treated and eligible patients at dose level 2
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Capecitabine, Nintedanib) | Objective Response Rate | 58.3 percentage of participants |